Next Article in Journal
Optimizing Outcomes with Azacitidine: Recommendations from Canadian Centres of Excellence
Previous Article in Journal
Piloting a Regional Collaborative in Cancer Surgery Using a “Community of Practice” Model
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 21
Issue 1
10.3747/co.21.1855
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Canadian Perspective on the Safe Administration of Bendamustine and the Prevention and Management of Adverse Events

by
J. Koolwine
1,*,
T. Crosbie
1,
G. Gazzé
2,
R. Turner
3,
J. Wiernikowski
4 and
W. Assaily
5
1
The Ottawa Hospital, Ottawa, ON, Canada
2
McGill University Health Centre, Montreal, QC, Canada
3
Princess Margaret Hospital, Toronto, ON, Canada
4
The Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada
5
‖New Evidence, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2014, 21(1), 35-42; https://doi.org/10.3747/co.21.1855
Submission received: 3 November 2013 / Revised: 6 December 2013 / Accepted: 9 January 2014 / Published: 1 February 2014

Abstract

Although bendamustine has been used to treat lymphoproliferative disorders for decades, it has only recently been approved for use in Canada. Thus, Canadian recommendations on the administration of bendamustine and the management of common adverse events (aes ) are needed. This article highlights effective management and assessment strategies recommended by Canadian nurses and pharmacists for the most common aes arising from the use of bendamustine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma. Those strategies include administering bendamustine over 60 minutes instead of 30 minutes, administering pre-medications to control infusion-related reactions and nausea, hydrating patients to minimize fatigue, and using free-flowing saline at the closest port to prevent phlebitis.
Keywords: bendamustine; adverse events; toxicities; chronic lymphocytic leukemia; indolent non-Hodgkin lymphoma; nhl; cll; inhl; fatigue; nausea bendamustine; adverse events; toxicities; chronic lymphocytic leukemia; indolent non-Hodgkin lymphoma; nhl; cll; inhl; fatigue; nausea

Share and Cite

MDPI and ACS Style

Koolwine, J.; Crosbie, T.; Gazzé, G.; Turner, R.; Wiernikowski, J.; Assaily, W. A Canadian Perspective on the Safe Administration of Bendamustine and the Prevention and Management of Adverse Events. Curr. Oncol. 2014, 21, 35-42. https://doi.org/10.3747/co.21.1855

AMA Style

Koolwine J, Crosbie T, Gazzé G, Turner R, Wiernikowski J, Assaily W. A Canadian Perspective on the Safe Administration of Bendamustine and the Prevention and Management of Adverse Events. Current Oncology. 2014; 21(1):35-42. https://doi.org/10.3747/co.21.1855

Chicago/Turabian Style

Koolwine, J., T. Crosbie, G. Gazzé, R. Turner, J. Wiernikowski, and W. Assaily. 2014. "A Canadian Perspective on the Safe Administration of Bendamustine and the Prevention and Management of Adverse Events" Current Oncology 21, no. 1: 35-42. https://doi.org/10.3747/co.21.1855

APA Style

Koolwine, J., Crosbie, T., Gazzé, G., Turner, R., Wiernikowski, J., & Assaily, W. (2014). A Canadian Perspective on the Safe Administration of Bendamustine and the Prevention and Management of Adverse Events. Current Oncology, 21(1), 35-42. https://doi.org/10.3747/co.21.1855

Article Metrics

Back to TopTop